GlassScriptPhysician profile
Senthil Anand
NPI 1053726273
$50,539.53
in general payments reported to CMS, 2019-2025
22 companies · $42K in 2025
The $42K reported for 2025 was more than what 91% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $100 · 2022: $412 · 2023: $3,503 · 2024: $3,930 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $4,400 · Travel and Lodging: $1,764 · Consulting Fee: $1,524 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,810.00 |
| Food and Beverage | $4,400.39 |
| Travel and Lodging | $1,763.90 |
| Consulting Fee | $1,524.00 |
| Education | $207.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26,142.87 | 2023-2025 | Winrevair, Verquvo |
| Actelion Pharmaceuticals US, INC. | $19,030.39 | 2023-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $1,679.84 | 2022-2023 | |
| Abbott Laboratories | $1,242.63 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $576.32 | 2019-2025 | Lifevest |
| United Therapeutics Corporation | $296.46 | 2023-2025 | Orenitram |
| Abiomed | $218.68 | 2023-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $211.01 | 2022-2025 | Onpattro |
| Novo Nordisk INC | $204.30 | 2024-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $143.36 | 2024 | Xarelto, Uptravi |
| Novartis Pharmaceuticals Corporation | $126.04 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.60 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $118.50 | 2025 | |
| Liquidia Technologies, INC. | $98.08 | 2025 | Yutrepia |
| Johnson & Johnson Health Care Systems INC. | $78.74 | 2025 | Uptravi, Opsynvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $73.89 | 2025 | Attruby |
| Pfizer INC. | $62.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $31.62 | 2022-2024 | Farxiga |
| Cardiac Dimensions, INC. | $23.79 | 2025 | |
| Livanova USA, INC. | $22.05 | 2022 | |
| Scpharmaceuticals INC. | $18.32 | 2025 | |
| Sandoz INC. | $15.69 | 2025 | Treprostinil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Senthil Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.